Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

, NBN, PTEN, RAD50, RAD51C, RAD51D, WRN) pathogenic/suspected pathogenic germline mutation, so as to explore the possibility of more combined therapy for breast cancer to achieve better therapeutic

  • 0 views
  • 09 Jul, 2022
  • 1 location
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

  • 0 views
  • 28 May, 2021
  • 1 location
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

BRCA1
cancer
ovarian cancer
cancer of the ovary
fallopian tube
  • 0 views
  • 09 Oct, 2021
  • 14 locations
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their …

genetic testing
progesterone
triple negative breast cancer
estrogen receptor
educational intervention
  • 24 views
  • 01 Jul, 2022
  • 2 locations
COsegregation of VARiants in Panel of Genes

The aim of the COVAR project is to classify reliably a maximum of VUS of the French database in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some …

BRCA1
KIT
cancer
BRCA1/2
cancer of the ovary
  • 17 views
  • 09 Aug, 2021
  • 88 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

beta human chorionic gonadotropin
olaparib
nitrosourea
tazemetostat
stem cell transplantation
  • 1032 views
  • 25 Jul, 2022
  • 106 locations
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

The primary objetive is to assess the capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1). The

BRCA1
her2/neu-negative breast cancer
erbb2
advanced breast cancer
BRCA1/2
  • 0 views
  • 04 May, 2022
  • 2 locations
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF

olaparib
neutrophil count
hysterectomy
metastasis
CDK12
  • 21 views
  • 09 Feb, 2022
  • 1 location
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking …

prostatectomy
cancer
niraparib
fancl
vasectomy
  • 6 views
  • 21 Mar, 2022
  • 1 location
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

mammogram
neutrophil count
erbb2
progesterone
advanced breast cancer
  • 5 views
  • 08 Sep, 2021
  • 1 location